Ching-Wen Chen

Ching-Wen Chen

Auto-generated profile, based on publicly available information

Ching-Wen Chen

Department of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CCChing-Wen Chen
Ching-Wen Chen
RMRohit Mittal
Rohit Mittal
NKNathan J. Klingensmith
Nathan J. Klingensmith
EBEileen M. Burd
Eileen M. Burd
CTCox Terhorst
Cox Terhorst
MFMandy L. Ford
Mandy L. Ford
Sepsis is a leading cause of death in the United States, but the mechanisms underlying sepsis-induced immune dysregulation remain poorly understood. 2B4 (CD244, SLAM4) is a cosignaling molecule expressed predominantly on NK cells and memory CD8+ T cells that has been shown to regulate T cell function in models of viral infection and autoimmunity. In this article, we show that 2B4 signaling mediates sepsis lymphocyte dysfunction and mortality. 2B4 expression is increased on CD4+ T cells in septic animals and human patients at early time points. Importantly, genetic loss or pharmacologic inhibition of 2B4 significantly increased survival in a murine cecal ligation and puncture model. Further, CD4-specific conditional knockouts showed that 2B4 functions on CD4+ T cell populations in a cell-intrinsic manner and modulates adaptive and innate immune responses during sepsis. Our results illuminate a novel role for 2B4 coinhibitory signaling on CD4+ T cells in mediating immune dysregulation.

8 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
WZWenxiao Zhang
Wenxiao Zhang
JAJerome C. Anyalebechi
Jerome C. Anyalebechi
KRKimberly M. Ramonell
Kimberly M. Ramonell
CCChing-Wen Chen
Ching-Wen Chen
JXJianfeng Xie
Jianfeng Xie
MFMandy L. Ford
Mandy L. Ford
TIGIT is a recently identified coinhibitory receptor that is upregulated in the setting of cancer and functionally contributes to the impairment of antitumor immunity. However, its role during sepsis is unknown. Because patients with cancer are 10 times more likely to die of sepsis than previously healthy (PH) patients with sepsis, we interrogated the role of TIGIT during sepsis in the context of preexistent malignancy. PH mice or cancer (CA) mice inoculated with lung carcinoma cells were made septic by cecal ligation and puncture (CLP). We found that sepsis induced TIGIT upregulation predominantly on Tregs and NK cells in both PH and CA mice. Anti-TIGIT Ab improved the 7-d survival of CA septic mice but not PH mice after CLP. Treatment of CA septic animals but not PH septic animals with anti-TIGIT mAb significantly reversed sepsis-induced loss of CD4 + T cells, CD8 + T cells, Foxp3 + Treg, and CD19 + B cells in the spleen, which was the result of decreased caspase-3 + apoptotic cells. In sum, we found that anti-TIGIT Ab reversed sepsis-induced T cell apoptosis in CA septic mice and led to a significant survival benefit, suggesting its use as a potential immunotherapy to improve outcomes in septic patients with cancer.

22 August 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
NKNathan J. Klingensmith
Nathan J. Klingensmith
KFKatherine T. Fay
Katherine T. Fay
DSDavid A. Swift
David A. Swift
JBJulia M.R. Bazzano
Julia M.R. Bazzano
JLJohn D. Lyons
John D. Lyons
CCCraig M. Coopersmith
Craig M. Coopersmith
Expression of the tight junction–associated protein junctional adhesion molecule-A (JAM-A) is increased in sepsis, although the significance of this is unknown. Here, we show that septic JAM-A –/– mice have increased gut permeability, yet paradoxically have decreased bacteremia and systemic TNF and IL-1β expression. Survival is improved in JAM-A –/– mice. However, intestine-specific JAM-A –/– deletion does not alter mortality, suggesting that the mortality benefit conferred in mice lacking JAM-A is independent of the intestine. Septic JAM-A –/– mice have increased numbers of splenic CD44 hi CD4 + T cells, decreased frequency of TNF + CD4 + cells, and elevated frequency of IL-2 + CD4 + cells. Septic JAM-A –/– mice have increased numbers of B cells in mesenteric lymph nodes with elevated serum IgA and intraepithelial lymphocyte IgA production. JAM-A –/– × RAG –/– mice have improved survival compared with RAG –/– mice and identical mortality as WT mice. Gut neutrophil infiltration and neutrophil phagocytosis are increased in JAM-A –/– mice, while septic JAM-A –/– mice depleted of neutrophils lose their survival advantage. Therefore, increased bacterial clearance via neutrophils and an altered systemic inflammatory response with increased opsonizing IgA produced through the adaptive immune system results in improved survival in septic JAM-A –/– mice. JAM-A may be a therapeutic target in sepsis via immune mechanisms not related to its role in permeability.